If you received Dupilumab, (brand name Dupixent), injections and later developed T-cell lymphoma, CTCL, or Sezary syndrome, you may qualify for significant compensation through a product liability lawsuit. The connection between this widely used eczema injection and dangerous T-cell lymphoma, CTCL and Sezary syndrome has prompted legal action. Schwaba Law Firm will fight aggressively for the justice and compensation you deserve. Call us today or contact us online for a free consultation to learn more.
This guide explains Dupixent’s health risks and the legal options for victims seeking compensation for CTCL, T-cell lymphoma through a Dupixent lawsuit.
WHAT IS DUPIXENT?
Dupixent is an injectable human monoclonal antibody which inhibits the signaling of interleukins, proteins that act as messengers in the immune system. It is prescribed for a variety of skin conditions such as atopic dermatitis and eczema, but the use has also been expanded to include asthma, rhinosinusitis and chronic obstructive pulmonary disease (COPD). Dupixent was approved in 2022 for use in children aged 2-5.
Regeneron and Sanofi-Aventis, the manufacturer and distributors of Dupixent, have marketed the antibody as a safe, long-acting solution for people seeking reliable relief from embarrassing and troubling skin conditions like atopic dermatitis and atopic eczema which create patches of itchy, red and dry skin. The shot works to suppress the immune system and target specific parts of the immune system involved in atopic dermatitis.
Despite its current widespread use, Dupixent has received scrutiny from physicians and academics outlining its dangerous effects like CTCL and Sezary syndrome. Published studies in academic journals like the Journal of the American Academy of Dermatology, Dermatology Online Journal, International Journal of Dermatology and the International Journal of Hematology, have demonstrated the causative link between Dupixent and T-cell lymphoma CTCL, and Sezary syndrome to Dupixent. These studies showed Dupixent users were 3-5 times more likely to develop CTCL and other complications than other atopic dermatitis eczema sufferers.
Regrettably, Regeneron and Sanofi-Aventis have failed to provide proper warnings to the public and physicians about Dupixent’s dangerous effects. They have failed to add or strengthen the warnings and adverse reactions associated with the drug. They have failed to advise the public that safer and other effective treatments for atopic dermatitis and eczema exist. Dupixent’s warnings and labels have not been updated, nor have efforts been taken to advise the public and physicians about the development and progression of CTCL from Dupixent use.
HEALTH COMPLICATIONS LINKED TO DUPIXENT (DUPILUMAB)
Recent scientific research has demonstrated links between Dupixent injections and serious health complications, particularly T-cell lymphomas, CTCL, mycosis fungoides, and Sezary syndrome. T-cell lymphoma is a rare blood cancer starting in immune white blood cells (T-cells) that result in swollen lymph nodes, skin rashes and other symptoms.
Treatment can include chemotherapy, radiation, immunotherapy and stem cell transplants. The prognosis for these diseases vary, but may result in lifelong dangers and troubling survival rates.
WHY ARE LAWSUITS BEING FILED AGAINST REGENERON AND SANOFI-AVENTIS?
Potential claims against Sanofi-Aventis and Regeneron are based on several compelling legal claims:
– Failure to Test – Drug Manufacturers and Distributors have the legal obligation to ensure their drug is safe prior to its sale. They are tasked with understanding the risks of a drug, like the risks of an aggravation or acceleration of the progression of T-cell lymphoma in the case of Dupixent. To comply with that legal obligation, drug manufacturers and distributors have to properly analyze and test their products for any dangerous side effects or complications. Regeneron and Sanofi-Aventis are alleged to have failed to properly test Dupixent before its release into the market
– Failure to Warn – Drug Manufacturers and Distributors also have the legal obligation to properly warn physicians, their patients and the wider public about any complications, adverse effects or dangers associated with their drugs. Regeneron and Sanofi-Aventis have not warned patients and their doctors about the risks of developing CTCL lymphoma in their product labeling, product inserts or wider publications. As a result, patients were receiving injections unaware of the true risks of the drug.
– Negligence – Drug Manufacturers and Distributors have the legal obligation to act with reasonable care in their actions. Regeneron and Sanofi-Aventis are alleged to have known or should have known about the increased risk of CTCL and Sezary syndrome based on available scientific research and failed to exercise reasonable care to properly warn patients.
AM I ELIGIBLE TO FILE A DUPIXENT LAWSUIT?
You may qualify to file a lawsuit if you meet the following criteria:
– You received Dupixent injections
– You were subsequently diagnosed with T-cell lymphoma, CTCL and/or Sezary syndrome
Schwaba Law Firm will evaluate your specific circumstances during a free consultation to determine your eligibility for compensation. The strength of the case depends on individual analysis of your specific matter, including the duration of your Dupixent use, the absence of other major risk factors, the grade and severity of your T-cell lymphoma, CTCL and/or Sezary syndrome and the impact on your health, career and quality of life
HOW TO PROVE YOUR CASE
Building a strong Dupixent lawsuit requires comprehensive evidence linking your Dupilumab use to your lymphoma diagnosis. Our experienced product liability attorneys will help you gather and present this vital evidence, including:
- Medical records from healthcare providers showing your Dupixent injections, including dates and frequency of administration
- Pharmacy records confirming your use of the injections
- Insurance and billing claims related to Dupixent injections
- Diagnosis documentation confirming your lymphoma diagnosis, including biopsy results, scans, surgical reports, and pathology results
- Expert testimony from dermatologists, oncologists, and other specialists establishing the causal link between your Dupixent use and lymphoma development
Our firm will partner with highly qualified medical experts who can explain the biological mechanism behind Dupixent’s role in promoting lymphoma growth through its effects on patients’ skin.
What Compensation Can Victims Recover?
Victims of Dupixent-related lymphomas may recover significant compensation for the full range of losses they suffered:
- Medical expenses, including chemotherapy, radiation treatment, and ongoing dermatological care
- Lost wages for work missed during treatment and any long-term career impacts
- Pain and suffering
- Future medical costs for continued treatment, monitoring, and potential tumor recurrence
- Loss of consortium, for the impact on relationships with spouses or partners
Based on preliminary analyses of similar brain injury lawsuits, Dupixent lymphoma cases involving significant complications could potentially result in settlement amounts ranging in the hundreds of thousands of dollars, with severe cases potentially reaching higher values.
Frequently Asked Questions (FAQs)
Some of the most pressing questions potential clients have for us include:
Is there a class action for Dupixent injuries?
While not technically a class action, Dupixent lymphoma cases may be consolidated into multidistrict litigation (MDL) in the future, although an MDL has not yet been established as the litigation is still quite new. This process enables individual lawsuits to proceed under coordinated pretrial proceedings, ensuring consistency while preserving each plaintiff’s right to a settlement amount based on their specific injuries.
How long do I have to file a lawsuit?
Statutory deadlines for product liability claims generally run from the date you discovered the connection between Dupixent and your lymphoma diagnosis, and each state’s laws vary as to the length of time. However, in Dupixent cases, the “discovery rule” may apply, meaning the clock starts when you discovered or reasonably should have discovered the connection between Dupixent use and your lymphoma. Because this connection has only recently been scientifically established, many victims still have time to file.
What proof do I need to start a claim?
To begin your claim, you will need medical records documenting your Dupixent use and T-cell lymphoma diagnosis. Schwaba Law Firm can help you gather additional evidence during the legal process.
Get Help from a Product Liability Lawyer
If you or a loved one developed lymphoma after using Dupixent, Schwaba Law Firm can provide the aggressive representation and compassionate guidance you need during this difficult time. Since 2010, our firm has fought tirelessly for product liability injury victims, securing considerable compensation for those harmed by dangerous pharmaceutical products.
Our approach reflects the values of the communities we serve, placing people above profits and fighting for what’s right. We will:
- Thoroughly evaluate your medical records and case details
- Connect you with qualified medical experts who can strengthen your claim
- Handle all communication with Regeneron and Sanofi-Aventis’ legal team and insurance representatives
- Prepare your case thoroughly as if it will go to trial, even while pursuing a fair settlement
- Keep you informed throughout every step of the legal process
- Advance all costs related to your case—you pay nothing unless we win
The developing Dupixent litigation presents an opportunity for victims to hold its makers accountable for failing to warn about the serious health risks associated with their product. Contact Schwaba Law Firm today for a free, no-obligation consultation to discuss your legal options and protect your rights.
